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Abstract
Despite intensive research and constant medical progress, sepsis
remains one of the most urgent unmet medical needs of today.
Most studies have been focused on the inflammatory component
of the disease; however, recent advances support the notion that
sepsis is accompanied by extensive metabolic perturbations.
During times of limited caloric intake and high energy needs, the
liver acts as the central metabolic hub in which PPARa is crucial to
coordinate the breakdown of fatty acids. The role of hepatic PPARa
in liver dysfunction during sepsis has hardly been explored. We
demonstrate that sepsis leads to a starvation response that is
hindered by the rapid decline of hepatic PPARa levels, causing
excess free fatty acids, leading to lipotoxicity, and glycerol. In addi-
tion, treatment of mice with the PPARa agonist pemafibrate
protects against bacterial sepsis by improving hepatic PPARa func-
tion, reducing lipotoxicity and tissue damage. Since lipolysis is also
increased in sepsis patients and pemafibrate protects after the
onset of sepsis, these findings may point toward new therapeutic
leads in sepsis.
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Introduction
Sepsis is defined as a life-threatening condition resulting from a
dysregulated host response to infection and remains the major
cause of deaths in intensive care units, with an overall mortality
close to 25% (Singer et al, 2016). Sepsis hits some 19 million
people yearly and is characterized by a major pro-inflammatory
status, intertwined with phases of immune suppression, which
vary depending on time, tissue, and patient (Cavaillon &
Giamarellos-Bourboulis, 2019). These insights have encouraged
the testing of a wide variety of immunomodulatory therapies in
clinical trials over the past decades. Unfortunately, none of these
treatments have demonstrated an actual survival benefit. As a
consequence, the current management of sepsis is supportive
rather than curative and focusses on the elimination of the
pathogen, fluid resuscitation to preserve organ perfusion, main-
taining adequate blood pressure, and mechanical support of fail-
ing organs (Evans, 2018). The lack of successful innovative
therapeutics could be due to the prevailing notion that sepsis is a
classical inflammatory condition, while more recent studies
suggest that other pathways such as coagulation, circadian
rhythm, and metabolism may play an important role (Cohen
et al, 2015).
Classical features of sepsis, such as high fever, inflammation,
immune activation, tachycardia, and the acute-phase response,
demand extra-physiological energy that is supplied by the break-
down of carbohydrates, proteins, and lipids (Wolowczuk et al,
2008). Additionally, sepsis patients are often unable to eat, and opti-
mal composition of parenteral and enteral feeding is still under
discussion (Elke et al, 2015; Wischmeyer, 2018). Indeed, a strong
decrease in ATP/ADP ratios in muscle, liver, and heart has been
described in human patients and experimental animals (Brealey
et al, 2002; Omachi et al, 2002; Correa et al, 2012). Moreover,
extensive metabolic dysregulation has been reported in septic
patients and several experimental animal models of systemic
inflammation (Li et al, 2018).
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The liver has an important function during inflammation since it
contributes to the innate immune system by producing acute-phase
proteins and by phagocytosis of bacterial toxins by resident Kupffer
cells (Sleyster & Knook, 1982; Ramadori & Christ, 1999). In addition,
the liver is the central organ for carbohydrate, protein, and fat meta-
bolism (Strnad et al, 2017). Liver dysfunction has been shown to
occur during the early stages of sepsis and persists late into the
immunosuppressive state (Wang et al, 1991). The initial dysregula-
tion of hepatocellular function has been linked to problematic
microcirculation and to the cytokine storm that is present early in
the disease progression (Wang et al, 1997). However, the precise
mechanism by which over-activation of the immune system and
liver dysfunction leads to liver failure remains unknown.
In times of energy deficit, lipids stored as triglycerides in adipose
tissue belong to one of the largest endogenous energy supplies of
the body (Cahill, 1970). The strong activation of the immune
system during sepsis and the suboptimal feeding of many patients
creates a state of energy deprivation that induces a starvation
response (Rittig et al, 2016). First-line energy-supplying molecules
such as glycogen and glucose are depleted within hours and are
supplemented by lipids being released from the fat tissue, a process
known as lipolysis (Nordenstrom et al, 1982). Several studies have
confirmed that upon inflammation and infection, the release of free
fatty acids (FFAs) from the white adipose tissue (WAT) into the
bloodstream is increased (Forse et al, 1987; Wellhoener et al,
2011). During the starvation response, FFAs are mainly taken up by
the liver to be oxidized in a process called b-oxidation to provide
energy and to produce ketone bodies, which are used as an energy
source by the brain and other organs (Askanazi et al, 1980; Forse
et al, 1987).
The oxidation of fatty acids is primarily controlled by the tran-
scription factor peroxisome proliferator-activated receptor alpha
(PPARa, encoded by the NR1C1 gene), which is highly expressed in
liver and brown adipose tissue. PPARa is considered one of the
major sensors of nutritional status that adapts metabolic homeosta-
sis to energy deprivation (Polvani et al, 2016). The PPAR subfamily
belongs to the family of nuclear receptors that share a conserved
modular structure, consisting of an N-terminal domain, important
for transcriptional activation, a DNA-binding domain that contains
zinc fingers, a short hinge region, and the C-terminal ligand-binding
domain. PPARa regulates transcription by forming a heterodimer
with the retinoid X receptor (RXR) and recognizes specific DNA
sequences referred to as PPAR response elements (PPREs; Dubois
et al, 2017). Multiple studies have shown aberrant expression
patterns of PPARa and its target genes in several tissues in the septic
state (Wong et al, 2009; Standage et al, 2012). However, the mecha-
nism behind this deficient signaling and the metabolic consequences
during sepsis remain to be elucidated. Recently, Paumelle and
colleagues have demonstrated that appropriate function of hepatic
PPARa is crucial for survival of sepsis, induced by a bacterial infec-
tion in mice (Paumelle et al, 2019). We have confirmed this finding
and found that hepatic PPARa function and signaling are altered at
a genome-wide level during sepsis, with deleterious effects on liver
metabolic functions and health as a consequence. We also showed
that modulating PPARa levels and activity with the agonist
pemafibrate improves mortality in a CLP-induced peritonitis sepsis
mouse model by improving hepatic PPARa function and metabolic
dysregulation.
Results
Hepatic PPARa action is hampered during sepsis
Hepatic PPARa was previously shown to be crucial for survival
during bacterial sepsis since mice lacking PPARa in the liver were
sensitized to a lethal E. coli challenge and showed severe metabolic
and inflammatory reprogramming (Paumelle et al, 2019). To inves-
tigate the functionality of liver PPARa during the CLP-induced peri-
tonitis sepsis mouse model, RNA sequencing was performed on
livers of mice treated with CLP or sham operation, injected with
either vehicle or the PPARa agonist GW7647 6h post-operation.
Gene expression was measured 4h after GW7647 administration.
When plotting the log fold changes (LFCs) of all upregulated
GW7647-responsive genes (LFC > 0.8, P < 0.05) in sham mice
versus their LFC after GW7647 in CLP, a clear shift toward a blunted
PPARa activity was observed after CLP. (Fig 1A, black line
(slope = 0.3115) versus red diagonal). Of the 270 genes that are
significantly induced after GW7647 stimulation in sham mice, only
10 were still upregulated after CLP (Fig 1B). Similarly, of the 48
genes that are downregulated by GW7647 in the sham condition, 1
is still downregulated after CLP. After CLP, 39 genes were specifi-
cally induced by GW7647 in the sepsis condition, with most of these
genes belonging to immune cell chemotaxis and pro-inflammatory
pathways, as shown by gene ontology (GO) term analysis (Fig EV1A
and Dataset EV1). Of the 270 GW7647-induced genes, 108 were
found to be downregulated in livers of CLP mice without any stimu-
lation, indicating that in addition to being non-responsive to stimu-
lation, PPARa downstream signaling is being downregulated after
CLP. Moreover, GO term analysis of all the genes that are
▸Figure 1. Hepatic PPARa signaling is disturbed at a genome-wide level during sepsis.A–D RNA-seq of liver 10 h post-sham or CLP. Mice (n = 3/group) underwent a sham or CLP operation and were injected with GW7647 (10 lg/g) 6 h post-surgery, and
after 4 h (total of 10 h), livers were isolated and RNA was prepared. (A) Scatter plot showing log fold change (LFC) of all GW7647-upregulated genes (LFC > 0.8 and
P < 0.05) in sham versus their LFC 10 h after CLP. The red line represents the diagonal, and the black line represents the real slope (0.3115) of the data. (B) Venn
diagram depicting the amounts of genes upregulated (up) or downregulated (dn) by GW7647 in sham and CLP mice (LFC > 0.8 or < 0.8 and P < 0.05). (C) Top
enriched gene ontology (GO) terms for genes that are downregulated in CLP mice without stimulation compared to unstimulated sham controls (LFC < 0.8 and
P < 0.05). Composite of 3 datasets: CLP1 (6 h after CLP), CLP2 (8 h after CLP), and CLP3 (10 h after CLP). Analysis was performed with the Enrichr tool. (D) Heat map
of differentially expressed genes in sham mice after GW7647 treatment, involved in b-oxidation of fatty acids (unit scale bar = log2 of the normalized counts).
E, F Confirmation of RNA-seq data via qPCR on pure hepatocytes isolated via flow cytometry-based sorting (n = 3/group). (E) Ppara and (F) Hmgcs2 mRNA expression is
shown as relative expression, normalized to housekeeping genes Hprt and Rpl. P-values were calculated using 2-way ANOVA analysis. Central lines represent mean.
Source data are available online for this figure.
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downregulated in liver after CLP compared with unstimulated sham
controls revealed that these genes show enrichment for fat meta-
bolic processes in which PPARa is involved such as fatty acid b-
oxidation and fatty acid transport (Fig 1C and Dataset EV2). As
illustrated by the heat map, Hmgcs2, Slc25a20, Cpt1a, and other
genes involved in b-oxidation are indeed significantly upregulated
by GW7647 in sham mice, unresponsive to GW7647 after CLP and
downregulated by CLP (Fig 1D). Clustering analysis revealed that
expression profiles of b-oxidation genes are almost identical in CLP
with or without GW7647 stimulation, while expression profiles of
genes after GW7647 stimulation in sham mice were most distinc-
tive. To confirm the contribution of hepatocytes to the GW7647
resistance, gene expression of Ppara and target genes was analyzed
in a pure hepatocyte population, sorted by flow cytometry (Figs 1E–
F and EV1B–F, Appendix Fig S1 for gating strategy). Together, these
data demonstrate a reprogramming of PPARa signaling during
sepsis in which pro-inflammatory signaling is favored to activation
of metabolic pathways. In addition, many GW7647-responsive
genes, including PPARa itself, are being downregulated during
sepsis, which may cause severe disturbances in fatty acid metabolic
pathways such as breakdown of fatty acids via b-oxidation, energy
generation, and ketone body formation.
PPARa levels are downregulated in liver during sepsis
Downregulation of PPARa expression in whole blood of patients
with septic shock was shown to be associated with decreased
survival and increased bacterial load (Standage et al, 2012). In addi-
tion, one study has demonstrated a dose-responsive downregulation
of PPARa protein levels in hamster livers after LPS challenge
(Beigneux et al, 2000). We hypothesized that the lack of transcrip-
tional activity of PPARa during sepsis is due to decreased PPARa
expression levels. By analyzing PPARa gene expression in liver at
several timepoints after CLP, we found a time-dependent gradual
decrease in Ppara mRNA levels over time, with significant decreases
in mRNA levels at 6, 10, and 24 h post-sepsis initiation (Fig 2A).
The decline in mRNA was reflected by significantly lower PPARA
protein levels in liver 24 h after sepsis (Fig 2B and C). Reduced
Ppara mRNA levels in liver during CLP-induced sepsis were found
to be a recurrent phenomenon, and a clear correlation was observed
between body temperatures and PPARa expression levels, both
measured 24 h after sepsis initiation (r = 0.6875, P < 0.0001;
Fig 2D). This correlation implies that mice with higher PPARa
expression levels have a higher body temperature, which may result
in increased survival chances. As a consequence of the PPARa
decline, some PPARa-responsive genes such as Hmgcs2 follow the
gradual decline in mRNA levels in liver after sepsis (Fig 2E).
Together, these data suggest a fast and strong downregulation of
PPARa mRNA and protein levels in liver during sepsis. Since PPARa
is the major transcription factor involved in b-oxidation of fatty
acids, we investigated the ability of liver explants to metabolize
palmitic acid (PA) ex vivo via Seahorse technology. Liver explants of
24-h-starved sham mice showed an increase in oxygen consumption
rate (OCR) when PA was added as a substrate instead of BSA, indi-
cating increased activity of the b-oxidative and oxidative phosphory-
lation pathway (Fig 2F–G, Appendix Fig S2 for all timepoints). This
increase in metabolic activity was not observed in liver explants of
CLP mice 24 h after sepsis initiation, suggesting that the decrease in
PPARa levels and activity causes abnormalities in metabolic path-
ways such as the breakdown of fatty acids via b-oxidation.
Sepsis acutely activates lipolysis in fat tissue
During a normal starvation response, fatty acids are being released
from adipose tissue into the blood, by a process known as lipolysis,
to provide energy by means of b-oxidation (Cahill, 1970). Since
sepsis reduces appetite and requires supra-physiological energy
supplies to fuel immune pathways, we believe sepsis mimics/
exploits the starvation response. To monitor fat loss during sepsis,
subcutaneous and visceral fat pads were weighed 24 h after the
onset of sepsis. A significant decrease in the percentage of body
weight taken up by the inguinal (iWAT), mesenteric (mWAT), and
perirenal (pWAT) fat pads was observed 24 h after CLP compared
with control sham mice, indicating a loss of fat tissue in septic mice
(Fig 3A–C). Starvation of sham mice for 24 h led to significant
decrease in weight of pWAT, however, not to the same extent as
mice that underwent CLP. Visualization of iWAT (Fig 3D) and
pWAT (Fig 3E) of sham, sham-starved, and CLP mice 24 h post-
surgery confirmed the loss of fat mass after CLP. Activation of lipol-
ysis is associated with an increase in free fatty acids (FFAs) and
glycerol in the bloodstream. Both the concentrations of total FFAs
and glycerol were increased in the blood of septic mice 6 h after the
induction of sepsis, with a continued increase in FFA and glycerol
plasma levels 24 h after sepsis (Fig 3F–G). Compared with 6-h-
▸Figure 2. PPARa levels are decreased in the liver during sepsis and correlate with disease severity.A Mice (n = 4/group, data are representative of two experiments) underwent a sham (with or without starvation) or CLP operation, and liver was isolated on several
timepoints post-surgery for RNA preparation and qPCR. Ppara mRNA expression is shown as relative expression, normalized to housekeeping genes Hprt and Rpl. P-
values were calculated using 1-way ANOVA analysis. Central lines represent mean.
B PPARA protein levels were analyzed in livers 24h after sham or CLP by Western blot using actin as a loading control.
C Quantification of PPARA Western blot. P-value was calculated via 2-way Student’s t-test (n = 4/group). Central line represents mean; error bars represent
mean  SEM.
D Pearson correlation between log fold change (LFC) Ppara expression levels and body temperature 24 h post-sepsis (n = 38, r = 0.6875, combined data of four
independent experiments).
E Liver Hmgcs2 mRNA expression at different timepoints post-sepsis, expression is shown as relative expression, normalized to housekeeping genes Hprt and Rpl. P-
values were calculated using 1-way ANOVA analysis (n = 4/group, data are representative of two experiments). Central lines represent mean.
F Oxygen consumption rates (OCRs) of liver tissue explants 24 h post-sham or CLP. Liver tissue was isolated 24 h post-surgery, and OCR was measured via Seahorse
with BSA or palmitic acid (PA) as a substrate for 42 min. n = 4/group. Central line represents mean; error bars represent mean  SEM.
G Visualization of T42(min) OCR, P-values were calculated using 2-way ANOVA analysis. Central lines represent mean.
Source data are available online for this figure.
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starved sham mice, CLP mice showed higher FFA levels, while glyc-
erol levels showed a trend toward higher levels after CLP. Analysis
of specific fatty acids in the blood 6 h and 24 h after sepsis initiation
via liquid chromatography-mass spectrometric lipidomics confirmed
the increased levels of several FFAs and fatty acid (FA) carnitines,
such as palmitic acid and palmitoyl-carnitine, in plasma of septic
mice (Fig 3H–I, Appendix Fig S3). Together, these data suggest an
acute and accelerated increase in lipolysis in fat tissue during sepsis,
leading to increased FFA and glycerol levels in the blood. Moreover,
the increase in FA carnitines might indicate mitochondrial dysfunc-
tion with impaired import and b-oxidation of fatty acids in the mito-
chondria.
Sepsis causes ectopic lipid accumulation and lipotoxicity
To protect tissues, lipid droplets are formed when fatty acid levels
are increased in circulation, as is the case when lipolysis is
increased (Plotz et al, 2016). Formation of lipid droplets and the
release of lipids from the lipid droplet into the cytoplasm for further
metabolic processing is tightly regulated by a coat of enzymes and
proteins surrounding the lipid droplet (Barneda & Christian, 2017).
Since lipolysis is increased during sepsis, we investigated the ectopic
lipid accumulation in cryosections of liver, kidney, and heart by
means of LipidTOX staining, a fluorescent dye with a high affinity
for neutral lipids. Both liver and kidney showed extensive lipid
droplet accumulation 24 h after sepsis initiation compared with
healthy sham controls (Fig 4A). A 24-h starvation of sham mice
leads to a significant increase in lipid droplets in liver, but not to the
same degree as seen in livers of septic mice. Lipid droplets were not
observed in kidneys of sham mice after a 24-h starvation, nor in
heart tissue in any condition (Figs 4A and EV2A). Quantification of
the amount of lipid droplets per cell and the average size of lipid
droplets, expressed as voxel counts, confirmed the increased
amount and size of lipid droplets in liver and kidney 24 h after
sepsis (Fig 4B). Oxidative stress and the presence of reactive oxygen
species have been described in liver and kidney in sepsis
(Mantzarlis et al, 2017). Combined with leakage of lipids into the
cytoplasm, the oxidative milieu could lead to lipotoxicity, a process
characterized by the formation of toxic lipid radicals (Engin, 2017).
As a measure of lipid peroxidation, we determined the presence of
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which are
the end products of lipid radical reactions. A significant increase in
both MDA and 4-HNE levels was observed in liver and kidney 24 h
after CLP compared with healthy controls (Fig 4C and D, Kidney in
Fig EV2B and C). In contrast, liver and kidney of 24-h-starved sham
mice showed no increase in MDA and 4-HNE levels. Lipid peroxides
are highly reactive and have been shown to cause cell death and
tissue damage (Ayala et al, 2014). In accordance with this, TUNEL
staining in liver and kidney 24 h after CLP showed a significant
increase in apoptotic cells compared with healthy controls, a
phenomenon that was not observed in livers and kidneys of 24-h-
starved mice (Fig 4E, Kidney in Fig EV2D). These data suggest that
the increased presence of fatty acids in the blood may lead to
ectopic deposition of lipid storages in liver and kidney after sepsis.
Moreover, lipid peroxidation of excess lipids may cause lipotoxicity
and could contribute to cell death in liver and kidney after sepsis.
Pemafibrate boosts PPARa function and improves metabolic
disease parameters during sepsis
We have shown that hepatic PPARa transcriptional function is
severely dampened during sepsis, potentially due to a drastic
decrease in hepatic PPARa mRNA and protein levels. Since the
PPARa coding gene PPARa is a PPARa-responsive gene itself, we
hypothesized that pretreatment of mice with the PPARa agonist
pemafibrate might increase PPARa gene expression, improve PPARa
function, and protect mice during the CLP-induced peritonitis sepsis
model. A 1-week pretreatment of mice with pemafibrate significantly
reduced mortality from 90% to 50% compared with vehicle-treated
controls (Fig 5A), and this protection was associated with higher
body temperatures in the pemafibrate-treated group. (Fig EV3A). In
addition, disease severity, assessed by usage of the Mouse Clinical
Assessment Score for Sepsis (M-CASS), was reduced in the pemafi-
brate group compared with vehicle-treated control mice (Fig EV3B).
Treatment with pemafibrate increased expression of Ppara in livers
of sham mice (Fig 5B). Importantly, gene expression of PPARa and
downstream genes was also increased after pemafibrate in livers of
CLP mice 24 h post-sepsis initiation, with many genes reaching
expression levels close to those seen in vehicle-treated sham mice
(only Acsl1 and Slc25a20 are shown, Fig EV3C and D). Pemafibrate
treatment decreased plasma FFA levels by 34% and glycerol levels
by 25% compared with vehicle-treated controls (Fig 5C and D).
Although PPARa agonists have been shown to reduce circulatory
lipids, clinical trials on non-alcoholic fatty liver disease (NAFLD)
have not reported any improvement in hepatic steatosis (Bajaj et al,
2007; Fernandez-Miranda et al, 2008). Mice that were pretreated
with pemafibrate for 1 week displayed less lipid droplets in liver
24 h after CLP, while the average size of the lipid droplets was
increased in the pemafibrate-treated group compared with vehicle-
treated septic mice (Fig 5E and F). In contrast, kidneys of pemafi-
brate-treated mice had less lipid accumulation and smaller lipid
droplets in comparison with untreated control mice 24 h after CLP
▸Figure 3. Lipolysis of subdermal and visceral fat pads is enhanced during sepsis.A–C Percentage of body weight that is taken up by the inguinal fat pad (iWAT, A), the mesenteric fat pad (mWAT, B), and the perirenal fat pad (pWAT, C) 24 h post-
surgery in sham (with or without starvation) and CLP mice. P-values were calculated with a 1-way ANOVA test. Combined data of two independent experiments,
n = 6/group. Central lines represent mean.
D, E Visual representation of (D) iWAT and (E) pWAT sizes in sham, sham-starved, and CLP mice 24 h post-surgery. Data are representative of three independent
experiments.
F–I Mice (n = 6–10/group) underwent a sham (with or without starvation) or CLP operation, and blood was collected 6 h and 24 h post-surgery. Plasma was isolated,
and (F) FFA concentration and (G) glycerol concentration were determined as described in the method section. P-values were calculated with 2-way ANOVA tests.
Combined data of two independent experiments. (H–I) Normalized abundances of (H) palmitic acid and (I) palmitoyl-carnitine determined via liquid
chromatography-mass spectrometric lipidomics. Values were normalized to IQ values, and P-values were calculated with 2-way ANOVA tests. n = 8/group. Central
lines represent mean.
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(Fig EV3E and F). Lipotoxicity, assessed via MDA concentration
measurement, was lower in livers and kidneys of pemafibrate-
pretreated mice 24 h after sepsis initiation (Fig 5G and H). Since
pemafibrate treatment partly restored PPARa gene expression and
reduced metabolic disease parameters, we investigated the function-
ality of the b-oxidation pathway via Seahorse. Liver explants of CLP
mice that were pretreated with pemafibrate displayed increased OCR
upon PA addition compared with vehicle-treated CLP mice, indicat-
ing that increased PPARa levels improved the flux through the
hepatic b-oxidation pathway, which may contribute to the decreased
levels of systemic FFAs after sepsis (Fig 5I, all timepoints in
Appendix Fig S4).
Pemafibrate protects against sepsis by reducing tissue damage
Organ dysfunction is a well-described phenomenon during sepsis
and has been included into the most recent sepsis (Sepsis-3) defi-
nition (Singer et al, 2016). Abnormal liver and kidney functions are
frequently observed in septic patients and are reflected by increased
alanine aminotransferase (ALT)/aspartate aminotransferase (AST)
and creatinine blood levels, respectively. Pemafibrate treatment
decreased ALT-AST and creatinine plasma levels compared with
vehicle-treated controls 24 h after sepsis, indicating improved liver
and kidney function (Fig 6A and B, AST levels in Fig EV3G). In
addition, a decline in apoptotic cell death was observed in livers
and kidneys, 24 h after sepsis initiation, of mice that were
pretreated for 1 week with pemafibrate (Fig 6D and E). In addition
to its well-known metabolic function, PPARa has also been
described to have limited anti-inflammatory potential through the
induction of anti-inflammatory genes and direct inhibition of AP-1
and NFKB (Delerive et al, 1999). Moreover, fibrates have been
demonstrated to reduce systemic and organ bacterial loads through
increased recruitment of neutrophils to the site of infection
(Tancevski et al, 2014). In accordance, IL-6 plasma levels were
lower after pemafibrate treatment compared with vehicle-treated
controls 24 h after CLP, indicating a more controlled inflammatory
environment during pemafibrate-pretreated sepsis (Fig 6C). Also,
mice that were treated with pemafibrate showed lower systemic,
hepatic, renal, and pulmonary bacterial levels 24 h after sepsis initi-
ation (Figs 6D and EV3H–J). These mechanisms could explain the
reduction in sepsis-induced apoptotic cell death we observed in liver
and kidney after pemafibrate treatment (Fig 6E and F). To evaluate
the therapeutic potential of pemafibrate, mice were supplemented
with pemafibrate at different timepoints before and after the induc-
tion of sepsis (Fig 6G). A 1-day pretreatment with pemafibrate
protected mice to the same extent as the 1-week pretreatment, while
administration of pemafibrate at the time or 2 h after sepsis
induction showed a lower but still significant protection. Pemafi-
brate demonstrated no protective effect when administered later in
the disease progression. To determine whether inhibition of PPARa,
by means of an antagonist, would lead to increased sensitivity to
sepsis, mice were injected with the PPARa antagonist GW6471 3 h
before and 3 h after sepsis was induced. Mice that were treated with
GW6471 displayed a significant increase in mortality during CLP
from ~44% to ~88%, and worsened disease and metabolic parame-
ters, showing that inhibition of PPARa function is detrimental for
survival during sepsis (Figs 6H and EV4). Together, these data
demonstrate that by manipulating PPARa expression levels and
function, mice can be protected or sensitized for CLP-induced peri-
tonitis. Moreover, pemafibrate pretreatment protects mice against
sepsis through enhanced hepatic PPARa function, which in turn
improves metabolic and inflammatory parameters, and reduces
organ dysfunction.
Lipolysis is increased in critically ill patients
Lipolysis of adipose tissue was shown to be increased in patients
with septic shock, who had higher glycerol and FFA blood levels
compared to patients without shock (Ilias et al, 2014). In confirma-
tion of this observation, we found FFA and glycerol concentrations
to be elevated in plasma of sepsis patients at day 1 of ICU admit-
tance (Fig 7A and B). Higher FFA levels were correlated with patient
SOFA scores and showed a trend toward correlation with AST and
lactate plasma levels in septic patients (Fig 7C). However, plasma
FFA levels were not correlated with IL-6 or IL-18 levels in these
patients. Glycerol plasma levels were not correlated with disease
severity or inflammatory status in sepsis patients (Fig 7D). These
data suggest that lipolysis is involved in the metabolic dysregulation
of tissue function but is not directly correlated with the inflamma-
tory status of septic patients.
Discussion
With 30 million cases per year and an overall mortality up to 25%,
sepsis remains a highly unmet medical need despite many years of
intensive research. Sepsis is associated with inflammation, but
based on numerous clinical trials with inflammatory inhibitors, and
since inflammation and metabolism are tightly intertwined, the
focus of more recent research has shifted toward the metabolic
perturbations during sepsis. Sepsis is characterized by a profound
metabolic dysregulation in many metabolic pathways such as carbo-
hydrate metabolism, amino acid metabolism, and fat metabolism.
For a more detailed description on the metabolic changes during
◀ Figure 4. Lipids accumulate in liver and kidney during sepsis and cause lipotoxicity.A, B Immunofluorescent images of liver and kidney 24 h after sham (with or without starvation) or CLP (n = 6–7/group, combined data of 2 independent experiments).
White scale bar = 20 lm. (A) Cryosections were stained with Acti-stain (green), Hoechst (blue), and LipidTOX (red). Z-stacks were generated in 5–10 areas scattered
across the entire tissue section. (B) The amount of lipid droplets (LDs)/cell and average size of LDs (represented by voxel counts) were calculated for each Z-stack.
Averages of the amount and size of LDs were converged for each mouse, and biological replicates are depicted in the table as mean  SEM. P-values were
calculated using 1-way ANOVA tests and can be found in Table EV1.
C, D Quantification of lipid peroxidation by determination of (C) MDA and (D) 4-HNE concentrations in liver homogenates 24 h post-surgery in sham and CLP mice as
described in methods (n = 6–7/group, combined data of two independent experiments). P-values were calculated with 1-way ANOVA tests. Central lines represent mean.
E Apoptosis in liver paraffin-fixated sections 24 h after sepsis, measured by TUNEL staining, and presented as % PI-positive cells/lm² tissue area. (n = 6/7
mice/group, combined data of two independent experiments). P-values were calculated with 1-way ANOVA tests. Central lines represent mean.
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sepsis, we refer the reader to a recent extensive review (Van
Wyngene et al, 2018).
One of the major causes of mortality of sepsis is the development
of multiple organ dysfunction, followed by organ failure (Wang
et al, 2014). Liver dysfunction is not very common in septic
patients; however, when it develops into liver failure, it becomes a
life-threatening condition. Importantly, liver dysfunction was shown
to have a remarkable prognostic relevance for the course of sepsis
and a strong predictive capacity for mortality (Koch et al, 2011;
Dizier et al, 2015). The liver has clear immunological defensive
roles during sepsis, such as scavenging of bacteria and production
of inflammatory cytokines, which are described in detail elsewhere
(Wang et al, 2014; Strnad et al, 2017). In contrast, the metabolic
changes and perturbations in liver during sepsis, with focus on fat
metabolism in particular, remain largely unexplored.
Peroxisome proliferator-activated receptor (PPAR)a is of major
interest since it is the main transcription factor regulating fat cata-
bolic pathways in the liver, and the knowledge of its role in sepsis is
currently incomplete. Hepatic PPARa was recently shown to be
crucial for survival during sepsis, induced by bacterial infection in
mice, by controlling the metabolic response in hepatocytes
(Paumelle et al, 2019). Opposed to the strong and rapid decline of
PPARa expression levels we observed during sepsis, this study
reported an increase in PPARa levels in liver after E. coli infection.
A potential explanation for this discrepancy is the use of different
animal models to induce sepsis. Bacterial injection models generally
do not mimic the human septic condition completely, since there is
often a steady stream of bacteria present in human sepsis, while
injection of bacteria causes a sudden increase in bacterial load
(Lewis et al, 2016). The widely used cecal ligation and puncture
(CLP) is regarded as the golden standard as it mimics the progres-
sion and characteristics of human sepsis, especially peritonitis,
better (Dejager et al, 2011). The use of different sepsis mouse
models could elicit diverse temporal profiles of immunological and
metabolic responses, ultimately leading to divergent causes of
lethality. In support of our data, Paumelle et al (2019) reported
lowered PPARΑ expression levels in livers of non-surviving criti-
cally ill patients, a finding that should however be interpreted with
caution since the livers were dissected post-mortem.
Several studies have reported decreased PPARa levels in whole
blood, liver, kidney, and heart during systemic inflammation
(Beigneux et al, 2000; Feingold et al, 2008; Drosatos et al, 2011;
Standage et al, 2012). However, the mechanisms behind the PPARa
regulation during sepsis remain largely unknown and are possibly
varying between tissues. One study reported that inhibition of the
JNK pathways increased cardiac PPARa expression and prevented
LPS-induced cardiac dysfunction (Drosatos et al, 2011). Other stud-
ies have shown a link between increased levels of certain cytokines,
such as IL-6 and IL-1b, and decreased PPARa expression (Chew
et al, 2014; Chung et al, 2015). Moreover, miRNA-dependent regu-
lation of PPARs has been described in metabolic diseases and could
play a role in PPARa downregulation during sepsis (Portius et al,
2017). PPAR expression has been demonstrated to be influenced by
physical activity and cardiorespiratory fitness (Luquet et al, 2003;
Queiroga et al, 2015); therefore, reduced locomotion should also be
considered as a potential cause of decreased PPARa expression in
the liver. Indeed, septic mice showed a reduction in fitness and
activity, demonstrated by the increase in M-CASS score (Fig EV3B),
while treatment with pemafibrate improved the overall health of
septic mice and thus improved locomotion and activity. Addition-
ally, future experiments should also consider the effect of body and
environmental temperature on PPARa expression, as PPAR levels
have been linked to body temperature and the experiments in this
study were not performed at rodent thermoneutral temperatures
(30°C; Kersten et al, 1999; Cannon & Nedergaard, 2009; Chen &
Yang, 2014). Next to decreased PPARa expression, we demonstrated
lower levels of various PPARa-responsive genes in livers of septic
mice. Since many of these genes are involved in b-oxidation of fatty
acids, our findings are in line with the decreased respiratory activity
of livers of septic mice in the presence of palmitic acid as a substrate
for energy production.
In times of limited caloric intake, a starvation response is initi-
ated in which lipids become the main source of energy to prevent
muscle wasting (Cahill, 1970). In a process referred to as lipolysis,
free fatty acids (FFAs) are being released from adipose tissue into
the bloodstream, and subsequently taken up by peripheral organs to
produce energy via b-oxidation. Several studies have shown that the
increased energy demands in the initial phase of sepsis are provided
◀ Figure 5. The PPARa agonist pemafibrate reduces mortality of sepsis by stimulating PPARa signaling and improving metabolic parameters. Mice werepretreated with pemafibrate (1 mg/kg) or vehicle (0,9% NaCl) for 1 week before being subjected to CLP.
A Survival was monitored during 9 days, after which no further deaths occurred. Survival curve was analyzed via a log-rank test. Combined data of three
experiments, n = 20/group.
B Liver samples were isolated 24 h after CLP (n = 5–7/group, combined data of two independent experiments), mRNA was prepared, and gene expression levels of
Ppara were analyzed via qPCR. Gene expression values are shown as relative expression, normalized to housekeeping genes Hprt and Rpl. P-values were calculated
via 2-way ANOVA test. Central lines represent mean.
C, D Plasma was isolated 24 h after sepsis, and (C) FFA concentration and (D) glycerol concentration were determined as described in the method section. P-values
were calculated with 2-way ANOVA tests. n = 5–7/group, combined data of two independent experiments. Arrows represent the % of decrease caused by
pemafibrate treatment during sepsis. Central lines represent mean.
E Immunofluorescent images of cryosections of liver 24h post-surgery that were stained with Acti-stain (green), Hoechst (blue), and LipidTOX (red). Z-stacks were
generated in 5–10 areas scattered across the entire tissue section. White scale bar = 20 lm.
F The amount of lipid droplets (LDs)/cell and average size of LDs (represented by voxel counts) were calculated for each Z-stack. Averages of the amount and size of
LDs were converged for each mouse, and biological replicates are depicted in the table as mean  SEM. P-values were calculated using two-way Student’s t-tests.
n = 6/group, combined data of two independent experiments.
G, H Quantification of lipid peroxidation by determination of MDA concentration in (G) liver and (H) kidney homogenates 24 h post-surgery in sham and CLP mice
(n = 6–7/group, combined data of two independent experiments), as described in methods. P-values were calculated with 2-way ANOVA tests. Arrows represent the
% of decrease caused by pemafibrate treatment during sepsis. Central lines represent mean.
I Oxygen consumption rates (OCRs) of liver tissue explants 24 h post-sham or CLP (vehicle or pemafibrate-treated) after supplementation of palmitic acid (PA), measured
via Seahorse. Visualization of T42(min) OCR. P-values were calculates using 2-way ANOVA analysis. One experiment, n = 3/group. Central lines represent mean.
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by lipid mobilization through activation of lipolysis in adipose tissue
of septic patients (Askanazi et al, 1980; Nordenstrom et al, 1982;
Rittig et al, 2016). Our analysis of FFA and glycerol levels in plasma
of septic patients on day 1 of ICU admittance supports these find-
ings, and the positive correlation between FFA levels and SOFA
scores in these patients suggests that activation of lipolysis contri-
butes to the metabolic dysregulation and poor prognosis during
sepsis. Moreover, we have shown that compared to a normal starva-
tion response, in which no acute inflammation is present, lipolysis
is faster and stronger activated during sepsis. This acute activation
of lipolysis in sepsis is necessary to provide substrates for b-oxida-
tion to produce energy and ketone bodies in liver and other lipid-
metabolizing organs such as kidney and heart (Fritz et al, 1962;
Rossi et al, 1968). However, due to the downregulation of PPARa in
liver, uptake and oxidation of fatty acids is slowed, and lipids accu-
mulate in circulation, liver, and kidney as shown by lipidomics and
LipidTOX analysis.
Hepatic lipid accumulation occurs as a transient metabolic adap-
tion to starvation in which excess lipids are safely stored in lipid
droplets to avoid toxic effects (Ohama et al, 1994). Build-up of lipid
droplets in liver was indeed observed during CLP; nonetheless, two
important differences could be noted in comparison with a normal
starvation response. First, livers accumulate more and bigger lipid
droplets during sepsis and second, kidneys showed lipid droplet
accumulation, a phenomenon that is never observed during a
normal starvation response. Excessive lipid accumulation in
◀ Figure 6. Pemafibrate reduces tissue damage during sepsis.A–F Mice were pretreated with pemafibrate (1 mg/kg) or vehicle (0.9% NaCl) for 1 week before being subjected to sham or CLP. (A–C) Plasma was collected 24 h post-
surgery, and (A) alanine aminotransferase (ALT), (B) creatinine concentrations, and (C) IL-6 levels were measured as described in methods. P-values were calculated
with 2-way ANOVA tests. n = 6-7/group, combined data of two independent experiments. (D) Systemic bacterial load (CFU/ml blood) 24 h post-sepsis in vehicle or
pemafibrate-treated mice. P-values were calculated with 2-way Student’s t-test. (E–F) Apoptosis in (E) liver and (F) kidney paraffin-fixated sections 24 h after sepsis,
measured with TUNEL staining, and depicted as % of PI-positive cells/lm² tissue area. P-values were calculated with 2-way ANOVA tests. n = 6–7/group, combined
data of two independent experiments. Central lines represent mean.
G Pemafibrate (1 mg/kg) or vehicle (0.9% NaCl) was administered at different timepoints before and after the induction of sepsis and survival was monitored during
9 days, after which no further deaths occurred. Survival curve was analyzed via log-rank tests, and P-values can be found in Table EV1. Combined data of 3
independent experiments, n = 15/group.
H Mice were injected with the PPARa antagonist GW6471 (10 lg/g) or vehicle (DMSO) 3 h pre-CLP and 3h post-CLP. Survival was monitored during 9 days, after
which no further deaths occurred. Survival curve was analyzed via a log-rank test. Combined data of two independent experiments, n = 16/group.
A B
C D
Figure 7. Lipolysis is increased in septic patients. Blood samples were collected from healthy volunteers and septic patients (n = 13 septic patients, =15
healthy controls).
A, B Plasma was prepared, and (A) FFA and (B) glycerol concentrations were determined as described in the methods. P-values were calculated with two-way Student’s
t-tests. Central lines represent mean.
C, D Correlation of (C) FFA and (D) glycerol concentrations with disease severity scores, lactate, or inflammatory cytokine levels from septic patients was calculated.
Values are shown as Pearson correlation values (r) with associated P-values.
ª 2020 The Authors EMBO Molecular Medicine e11319 | 2020 13 of 20
Lise Van Wyngene et al EMBO Molecular Medicine
circulation and organs, in particular in combination with the pres-
ence of reactive oxygen species (ROS) during sepsis, can lead to the
production of toxic lipid by-products, a process which is called lipo-
toxicity and often occurs through lipid peroxidation (Engin, 2017;
Gai et al, 2019). Two well-described lipid peroxidation by-products,
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), were
significantly increased in liver and kidney during sepsis and are
highly reactive, causing toxicity by physical interaction with amino
acid and nucleosides (Ayala et al, 2014). In addition, the fatty acid
palmitate was upregulated in circulation during sepsis and has been
demonstrated to have lipotoxic effects through various mechanisms
(Park et al, 2014). Together, accumulation of certain fatty acids and
toxic lipid peroxidation by-products could contribute to the
increased induction of apoptotic cell death in liver and kidney
during sepsis. These results demonstrate that sepsis acutely acti-
vates lipolysis which, in combination with the failing b-oxidation
due to PPARa downregulation, leads to the accumulation of lipids in
systemic circulation and peripheral organs. This accumulation may
in turn cause lipotoxicity, could contribute to organ dysfunction,
and ultimately lead to organ failure.
Fibrates are synthetic ligands of PPARa and are commonly used
for treatment of metabolic disorders that display dyslipidemia,
such as non-alcoholic fatty liver disease (NAFLD), cardiovascular
disease, and type 2 diabetes (Kondo et al, 2010; Elam et al, 2011).
In addition to the lipid-lowering properties of fibrates, potent anti-
inflammatory effects have been associated with fibrates as they
reduce the expression of inflammatory genes, inhibit the release of
pro-inflammatory cytokines, and regulate the activation and func-
tion of inflammatory cells (Michalik & Wahli, 2006). Gemfibrozil
and fenofibrate were shown to improve the course of bacterial
sepsis by attenuating the inflammatory response, independent of
the metabolic effects of fibrates (Tancevski et al, 2014; Camara-
Lemarroy et al, 2015). We found that administration of pemafi-
brate, a novel selective PPARa modulator (SPPARMa) with
improved selectivity, potency, and safety profile (Ishibashi et al,
2016), improved PPARa function and reduced the metabolic
dysregulation during sepsis. Although pemafibrate does not
improve steatosis in the liver after sepsis, it did reduce the accu-
mulation of toxic lipid peroxidation products and cell death in
liver and kidney. Comparable to fenofibrate, pemafibrate reduced
bacterial loads in circulation and target organs (Tancevski et al,
2014), indicating that through modulation of PPARa expression
and metabolic pathways, pemafibrate may assist in the control of
tissue infection and damage. Indeed, several studies have shown
that metabolism is clearly linked to immunity and that the meta-
bolic status of inflammatory cells changes their response to infec-
tion (Ganeshan & Chawla, 2014; Pearce & Pearce, 2018). However,
as fibrates have many mechanisms of action and the liver is not
the only organ affected during sepsis (Morel & Singer, 2014;
Tancevski et al, 2014; Camara-Lemarroy et al, 2015), it is essential
to study the role of the liver in the protection of pemafibrate
during sepsis, for example via the use of PPARa hepatocyte-
specific knock-out animal models. A preliminary experiment
suggests that the liver is crucial for the protective effect of pemafi-
brate in sepsis, since depletion of PPARa in the liver prevented
pemafibrate-mediated protection (Appendix Fig S5). Importantly,
pemafibrate showed potential in a more therapeutic setting since it
is able to protect mice against sepsis when administered early in
the disease progression. These results demonstrate that the meta-
bolic effects of fibrates through activation of PPARa contribute to
the protective mechanism of fibrates in sepsis.
In conclusion, our results demonstrate that sepsis leads to an
abnormal starvation response and major metabolic aberrations
through acute activation of lipolysis in fat tissue and downregula-
tion of PPARa in the liver. We suggest the use of fibrates as adjunct
therapy for the treatment of sepsis as they hold considerable thera-
peutic potential by improving hepatic PPARa function and meta-
bolic function during sepsis. However, the knowledge on
dysregulation of PPARa signaling and metabolic pathways during
sepsis is far from complete and warrants further study in both
animal models of sepsis and septic patients.
Materials and Methods
Mice
Male mice (C57BL/6J) were ordered from Janvier (Le Genest-St.Isle,
France) and were housed in light-controlled (14-h light; 10-h dark),
air-conditioned, specific pathogen-free conditions with food and
water ad libitum. All experiments were approved by the institu-
tional ethics committee for animal welfare of the Faculty of
Sciences, Ghent University, Belgium. The methods were carried out
in accordance with the relevant guidelines and regulations. Mice
were 8–10 weeks old at the time of the experiments.
Cecal ligation and puncture
Mice were subjected to CLP in order to induce polymicrobial septic
shock, as described by a published standard operating procedure
(Rittirsch et al, 2009). Briefly, mice were anesthetized by isoflurane
inhalation and a one-centimeter incision was made in the abdomen
after which the cecum was exposed and 75% ligated. This was
followed by making two punctures in the cecum with a 21-gauge
needle. During the procedure, some cecal content is pushed out
using sterile forceps. The abdominal musculature and skin were
closed with simple running sutures and metallic clips, respectively.
The mice were resuscitated by intraperitoneal injection of an antibi-
otic cocktail containing ceftriaxone (25 mg/kg; Sigma-Aldrich NV)
and metronidazole (12.5 mg/kg; Sigma-Aldrich NV) in 100 ll phos-
phate-buffered saline (PBS) 10 h and 24 h after CLP onset. Disease
severity was scored according to the M-CASS scoring system (Mai
et al, 2018). For experiments aimed to isolate blood and organ
samples, sham-operated mice of which the cecum was exposed but
not ligated or punctured were used and are indicated as sham, or
sham-starved when food was taken away at the time of the surgery.
For biochemical characterization, mice were euthanized via cervical
dislocation at different timepoints post-sepsis initiation and plasma
and organs were collected.
Reagents
Gw7647
GW7647 (Tocris Bioscience) was prepared as a solution of 2.5 mg/
ml in DMSO. Mice underwent a sham or CLP procedure and
received 7.5 mg/kg GW7647 6 h after sham or CLP surgery via
intraperitoneal injection.
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Pemafibrate
Pemafibrate (K-877, Chemscene) was prepared as a solution of
200 lg/ml in 0.1% ethanol in 0.9% NaCl. Mice received 1 mg/kg
of pemafibrate or 0.1% ethanol/0.9% NaCl (vehicle) via oral
gavage at different timepoints before and after sepsis initiation.
During the 1-week challenge, mice were gavaged on alternating
days, with 4 gavages in total. On day 7, the mice underwent a
sham or CLP procedure. During lethality experiments, mice
received an additional daily gavage of pemafibrate or vehicle. For
biochemical characterization, mice were euthanized by cervical
dislocation 24 h post-surgery and plasma and organs were
collected.
Gw6471
GW6471 (Tocris Bioscience) was prepared as a solution of 2.5 mg/ml
in DMSO. Mice were injected intraperitoneally 3 h before and 3 h
after sham or CLP surgery.
Liver transcriptomic analysis
RNA sequencing
Total RNA was isolated with the RNeasy Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. Biological triplicates were
used for every condition. RNA concentration was measured, and
RNA quality was checked with the Agilent RNA 6000 Pico Kit (Agi-
lent Technologies) and sequenced on a Illumina Genome Analyzer
IIx. Data were mapped to the mouse (mm10) reference genome
transcriptome with tophat2 (Kim et al, 2013). Only uniquely
mapped reads were retained. Gene-level read counts were obtained
with the HTSeq python package. Differential gene expression was
assessed with the DESeq2 package, and the FDR was set at the 1%
level. Gene ontology (GO) term enrichment on selected gene groups
was performed via the Enrichr tool (Chen et al, 2013).
Real-time qPCR
Liver was isolated and stored in RNA later (Life Technologies
Europe) before RNA was isolated with the Aurum Total RNA Mini
Kit (Bio-Rad) according to the manufacturer’s protocol. SensiFAST
cDNA Synthesis Kit (GC Biotech BV) was used to reverse-transcribe
1000 ng of RNA into cDNA. cDNA was diluted 20 times in ultrapure
water for use in RT–PCRs. RT–PCR primers for used targets are
listed in supplementals. RT–PCR was performed with SensiFAST
SYBR No-ROX Mix (Bioline) and was performed in duplicate in a
Roche LCII 480. Relative expression of targets was calculated by
comparison with HPRT and RPL expression in qBase+ software
(Biogazelle, Gent, Belgium). Primer sequences for qPCR can be
found in Appendix Table S4.
Biochemical analysis
Analysis of mouse plasma aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and creatinine levels was kindly
provided to us by the University Hospital of Ghent. Free fatty acid
(FFA) (Abnova) and glycerol (Cayman Chemical) were determined
via colorimetric assays. Plasma IL-6 levels were measured by
ELISA (eBioscience). Organ MDA and 4-HNE levels were deter-
mined via the principle of the lipid peroxidation assay (Eagle
Biosciences).
FAO metabolic assay
An XF-24 Extracellular Flux Analyzer (Seahorse Bioscience) was
used for fatty acid oxidation (FAO) measurement of liver explants.
Liver tissue (~10 mg) was incubated in FAO buffer (111 mM NaCl,
4.7 mM KCl, 1.25 mM CaCl2, 2.0 mM MgSO4, 1.2 mM NaH2PO4,
2.5 mM glucose, 0.5 mM carnitine, 5 mM HEPES) immediately
after isolation. OCR was measured at basal level after addition of
BSA or palmitic acid (PA) (Seahorse XF Palmitate-BSA FAO
Substrate, Agilent). Protein concentration of tissue extracts was
measured via the Bradford protocol and was used to normalize
OCR values.
Bacterial load quantification
Systemic bacterial load was determined through plating of 100 ll of
blood on tryptic soy agar (TSA) plates. 24 h post-inoculation at
37°C, colony-forming units (CFUs) were counted and CFU/ml was
determined. Organ bacterial loads were analyzed as followed:
100 mg of liver and kidney, and 30 mg of lung tissue were isolated
24 h post-sepsis and homogenized in 1ml of sterile PBS. Bacterial
load was determined via plating of 100 ll of tissue homogenates on
lysogeny broth (LB) agar plates. 24 h post-inoculation at 37°C, CFUs
were counted and CFU/mg of tissue was calculated.
Flow cytometry
Liver digestion and hepatocyte purification
Liver perfusion and hepatocyte isolation were performed as
described by Bonnardel et al (2019).
Cell sorting and RT–qPCR
Single-cell hepatocyte suspensions (0.5–5 × 106 cells) were stained
with appropriate antibodies (Appendix Table S1) at 4°C for 20 min
in the dark. FCBlock 2.4G2 antibody was used to minimize non-
specific binding of antibodies to FcR-bearing cells. Hepatocytes were
sorted as live-gated CD45 Lyve-1 cells using an ARIA III (BD,
Biosciences). The gating strategy can be found in Appendix Fig S1.
Final analysis and graphical output were performed using FlowJo
software (Tree Star, Inc.). For each sample, 20,000 hepatocytes were
sorted into RLT (1% b-mercaptoethanol) lysis buffer and RNA was
prepared using the RNeasy Plus Micro Kit (Qiagen Benelux B.V.) as
described by the manufacturer’s protocol. All RNA was used to
synthesize cDNA with the SensiFAST cDNA Synthesis Kit (GC
Biotech BV) and diluted 10× in ultrapure water before RT–PCR was
performed with SensiFAST SYBR No-ROX Mix (Bioline) in duplicate
in a Roche LCII 480. Relative expression of targets was calculated by
comparison with b-actin expression.
Western blot analysis
For the detection of PPARa, protein was isolated out of snap-frozen
liver tissue with RIPA lysis buffer, supplemented with protease inhi-
bitor cocktail (Roche). Protein samples containing 30 lg of protein
were separated by electrophoresis in a 10% gradient SDS polyacry-
lamide gel and transferred to nitrocellulose membranes (pore size,
045 lm). After blocking the membranes with a ½ dilution of Start-
ing Block/PBST 0.1% (Thermo Fisher Scientific), membranes were
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incubated overnight at 4°C with a primary antibody against PPARa
(1:1,000, catalog sc-398394, Santa Cruz Biotechnology). Blots were
washed with PBST 0.1% and then incubated for 1 h at room
temperature with anti-mouse HRP antibody (1:10,000, catalog
GENA931, Sigma-Aldrich NV.). Immunoreactive bands were visual-
ized detected and quantified using an Amersham Imager 600 (GE
Healthcare Life Sciences). After visualization of PPARa, the process
was repeated with a primary antibody against Actin (1:5,000, cata-
log MA5-15739, Life Technologies Europe).
Histological analysis
TUNEL
TUNEL staining for detection and quantification of apoptosis in
mouse liver and kidney paraffin-embedded sections was performed
using the “In Situ Cell Death Detection Kit, TMR Red” (Sigma-
Aldrich N.V.), according to a standard protocol. DNA strand breaks
were labeled with fluorescein (TMR Red) and imaged by fluores-
cence microscopy.
LipidTOX
Cryostat sections 20 lm in thickness were rehydrated in PBS for
5 min after which the sections were blocked in blocking buffer (2%
BSA, 1% fetal calf serum, 1% goat serum, in 0.5% saponin) for
30 min at RT. The antibody mix (LipidTOX Deep Red (1:400, Life
Technologies Europe B.V.); Acti-stain 488 Phalloidin (1:150,
Cytoskeleton Inc.)) was added and incubated for 2 h at RT. After
washing with PBS for 5 min, nuclear staining (Hoechst (1:1,000,
Sigma-Aldrich N.V.)) was added for 5 min at RT. Slides were
washed in PBS for 5 min, quickly rinsed in water to remove residual
salt, and mounted. For each cryosection, Z-stacks of 5–10 areas
were imaged with a spinning disk confocal microscope (Zeiss),
using a 40× Plan-Apochromat objective lens (1.4 Oil DIC (UV) VIS-
IR M27)) at a pixel size of 0.167 lm and at optimal Z-resolution
(240 mm). Z-stacks were processed in Volocity (PerkinElmer), and
the amount of lipid droplets and average size of lipid droplets (de-
picted as voxels) was calculated.
Lipidomics
Extraction
In short, a total volume of 3 ml of methyl tert-butyl ether with
0.01% BHT (w/v) was added to 40 ll of mouse plasma. This
mixture was vortexed for 30 s, and the sample was shaken for
20 min at 200 rpm at 20°C in an incubator (New Brunswick Innova
42, Eppendorf). Next, 1 ml of ultrapure water with 5% trichloroa-
cetic acid (w/v) was added to induce phase separation, which was
enforced by centrifugation for 5 min at 960 g at 20°C. Subsequently,
500 ll of the upper layer, consisting of methyl tert-butyl ether, was
collected and 50 ll of methanol internal standard mixture (25 ng/
ll) was added before being evaporated to dryness at 30°C under a
gentle stream of nitrogen. The residue was dissolved in 100 ll of
chloroform and 250 ll of methanol, after which 100 ll of the solu-
tion was transferred to an amber glass vial. An aliquot (5 ll) of
sample was injected into the chromatographic system. Liquid chro-
matography was achieved on a Dionex UltiMate 3000 XRS UHPLC
system (Thermo Fisher Scientific), and MS analysis was carried out
by high-resolution hybrid quadrupole Q-Exactive Orbitrap MS
(Thermo Fisher Scientific) as previously published (Van Meulebroek
et al, 2017).
Targeted analysis
Analytical reference standards were purchased from Sigma-Aldrich.
A selection of the reference standards can be found in
Appendix Table S3, and for the full standard list, we refer the reader
to Van Meulebroek et al (2017). To correct for instrumental drift,
biological samples, i.e., quality control (QC) samples, were used.
These QC samples are considered as representative bulk control
samples and were prepared by pooling all samples. QC samples
were dispersed evenly across the sample batch, and duplicate QC
injections were performed after every ten samples. The average
signal of those two injections was used for normalizing the ten
preceding samples. Samples were injected in a randomized order.
XCalibur 3.0 software (Thermo Fisher) was used for targeted
processing of full-scan data, including identification and
The paper explained
Hepatic PPARa function and lipid metabolic pathways are dysregu-
lated in polymicrobial sepsis.
Problem
Sepsis hits 19 million people yearly, 3 million of whom are children,
with a mortality rate of approximately 25%. Due to the lack of inno-
vative insights and therapeutics, sepsis remains a high unmet medical
need. In our opinion, this lack of treatment is largely due to the fact
that inflammation has been considered as the main driving and
killing mechanism in sepsis. However, recent evidence points toward
profound metabolic dysregulations as an alternative lethal aspect of
sepsis.
Results
In our paper, we use the cecal ligation and puncture mouse sepsis
model to investigate the metabolic alterations during sepsis. We have
found that septic animals enter a starvation response, in which fat
reserves are addressed and high-energy free fatty acids, together with
glycerol, are released from the white adipose tissue. In order to be
useful, the energy-rich free fatty acids have to be taken up by hepato-
cytes and oxidized to yield energy and ketone bodies. This metabolic
oxidation (b-oxidation) is organized in the liver mainly by one tran-
scription factor, i.e., PPARa. In our sepsis model, we observed that
PPARa loses its biological activity and that PPARa quickly declines in
mRNA and protein concentration. As a result, free fatty acids (and
glycerol) accumulate, leading to toxicity and cell death. Activation and
inactivation of PPARa before the onset of sepsis confirm the impor-
tance of this transcription factor, and more importantly, activation of
residual PPARa after the onset of sepsis can lead to a significant
protection and survival. Lastly, we confirmed the acute activation of
lipolysis in sepsis in humans, as free fatty acid and glycerol levels
were increased in blood of septic patients compared with healthy
controls.
Impact
These data show that liver PPARa, in addition to influencing
inflammation, plays a crucial role in the control of free fatty acid
oxidation during sepsis. Moreover, we have clearly demonstrated that
PPARa activity drops dramatically during sepsis, causing severe meta-
bolic alterations. We believe our findings may have a major impact
on the sepsis research field and could pave the way to new therapeu-
tic interventions in sepsis as our data using a novel PPARa agonist
are promising.
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quantification of lipid target compounds. Identification of a
compound was done by use of the m/z value of the molecular ion
(mass deviation ≤ 3 ppm) and the retention time relative to that of
an internal standard (deviation ≤ 2.5%), all being determined from
the corresponding analytical standard.
Human study
The clinical study protocol was approved by the ethics committee of
the University Hospital of Ghent. Patient selection and sample
collection on day 1 of the ICU stay were conducted as described in
the below. Patients’ characteristics such as their initial Sequential
Organ Failure Assessment (SOFA) score, site of infection, the
presence of septic shock, and treatments are summarized in
Appendix Table S2.
Patient selection
After admission to the ICU, thirteen patients were enrolled within
24 h after meeting the criteria for severe sepsis or septic shock
defined at the consensus conference of 2001 (Levy et al, 2003) and
after a signed informed consent was obtained from the patient itself
or a legal representative. The experiments conformed to the princi-
ples set out in the WMA Declaration of Helsinki and the Department
of Health and Human Services Belmont Report. Recently, a new
consensus definition has been published, but they were published
after the initiation of the study so we applied the old definition
(Singer et al, 2016). Patients’ characteristics such as initial SOFA
score, site of infection, the presence of septic shock, and treatments
are summarized in Appendix Table S2.
Inclusion and exclusion criteria of patients with severe sepsis and
clinical sample preparation
The criteria determined in the consensus conference of 2001 were
followed to select the patients (Levy et al, 2003). Male or female
patients ≥ 18 years of age were included after meeting two of
following criteria of severe sepsis: hyper- or hypothermia (> 38°C or
< 36°C); heart rhythm > 90/min; respiratory rate > 20/min; and
leukocytosis or leukopenia (> 12,000/mm³ or < 4,000/mm³), in
addition to a suspected or present source of infection and elevated
lactate levels (> 12 mg/dl) OR urinary output < 0.5 ml/kg/h during
> 2 h despite adequate fluid resuscitation OR acute lung injury with
PaO2/FiO2 < 250 in the absence of pneumonia as an infection
source OR acute lung injury with PaO2/FiO2 < 200 in the presence
of pneumonia as an infection source OR thrombocytopenia
(< 100,000/ll) OR coagulopathy (INR > 1.5). Patients with septic
shock were included when they fulfilled the criteria of severe sepsis
in addition to persistent hypotension despite adequate fluid resusci-
tation (systolic pressure < 90 mmHg or reduction of > 40 mmHg
compared with baseline) OR the need for vasopressors despite
adequate fluid resuscitation.
Patients were excluded after meeting the following criteria: age
< 18 years, the use of immunosuppressive medication and patients
with HIV, hematological malignancies, liver cirrhosis, or chronic
kidney insufficiency.
From patients meeting the inclusion criteria, blood was with-
drawn within 24 h of diagnosis (day 1) and the sequential organ
failure (SOFA) score was determined. Blood was collected in
heparin-coated vials for biochemical analysis. Control patients had
blood withdrawn at ambulatory centers. Thirteen patients and fif-
teen healthy controls were included in this study.
Statistical analysis
Groups were compared with two-way unpaired Student’s t-test,
multiple-group comparisons were performed using one- or two-way
analysis of variance (ANOVA), and the log-rank test was used for
survival tests using the Prism Software (GraphPad Software). Signif-
icance of correlation between parameters was determined via calcu-
lation of the Pearson (r) correlation coefficient using the GraphPad
Software. Samples were assumed to be normally distributed with
similar variance between groups. No randomization was used to
determine experimental groups, and no blinding of the investigator
was performed. Group sizes were determined on the basis of previ-
ous experience. No data were excluded from the analyses.
Study approval
All experiments in this paper were approved by the ethical commit-
tee of the Faculty of Sciences, Ghent University.
Data availability
RNA-seq data: Gene expression. Deposited at the National Center
for Biotechnology Information Gene Expression Omnibus public
database (http://www.ncbi.nlm.nih.gov/geo/) under accession
number GSE139484. Lipidomics: Deposited at the MetaboLights data-
base (https://www.ebi.ac.uk/metabolights/) under accession number
MTBLS1386.
Expanded View for this article is available online.
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